Valuation: ICAD

Market Cap 106M 92.52M 85.89M 78.93M 149M 10.19B 151M 1.02B 400M 4.99B 396M 388M 17.22B P/E 2023
-9.35x
P/E 2024 -8.59x
Enterprise Value 88.75M 77.76M 72.19M 66.34M 125M 8.56B 127M 860M 337M 4.19B 333M 326M 14.48B EV / Sales 2023
1.47x
EV / Sales 2024 1.6x
Free-Float
99.32%
Yield 2023 *
-
Yield 2024 -
3 years 1.18
Extreme 1.18
4.02
5 years 1.05
Extreme 1.05
15.55
10 years 1.05
Extreme 1.05
21.44
Manager TitleAgeSince
Chief Executive Officer 61 09/03/2023
Director of Finance/CFO 54 16/07/2025
Corporate Secretary - 16/07/2025
Date Insider Type Main position Quantity % Market Cap.
17/07/25 Issuer sale

Chief Technology Officer

351,145 1.3231%
17/07/25 Issuer sale

Director

82,056 0.3092%
17/07/25 Issuer sale

Chief Executive Officer

519,350 1.9569%
Change 5-day change 1-year change 3-year change Capi.($)
+3.75%-.--%-.--%+7.20% 106M
+0.57%-1.65%+23.11%-6.36% 196B
+0.07%-10.78%-5.67%-29.99% 126B
-2.68%-12.41%-33.33%+1.20% 120B
-0.51%-0.16%-58.35%-19.17% 63.87B
-0.21%-3.32%+10.58%-8.86% 48.58B
+0.17%-0.52%-24.32%-32.66% 43.93B
+0.45%-0.93%+14.86%+4.58% 37.69B
+0.89%-1.09%+29.00%+28.44% 36.41B
-0.86%+1.99%+87.07%+0.20% 28.88B
Average +0.46%-3.05%+4.30%-5.54% 70.14B
Weighted average by Cap. +0.20%-4.99%-0.50%-9.63%

Financials

2023 2024
Net sales 17.32M 15.17M 14.09M 12.94M 24.39M 1.67B 24.75M 168M 65.68M 818M 65.01M 63.61M 2.82B 19.61M 17.18M 15.95M 14.66M 27.62M 1.89B 28.02M 190M 74.37M 926M 73.61M 72.02M 3.2B
Net income -4.85M -4.25M -3.94M -3.62M -6.83M -468M -6.93M -46.97M -18.38M -229M -18.2M -17.8M -791M -5.62M -4.92M -4.57M -4.2M -7.91M -542M -8.03M -54.42M -21.3M -265M -21.08M -20.63M -916M
Net Debt -21.21M -18.58M -17.25M -15.85M -29.87M -2.05B -30.31M -206M -80.44M -1B -79.62M -77.9M -3.46B -16.84M -14.76M -13.7M -12.59M -23.72M -1.63B -24.07M -163M -63.88M -795M -63.23M -61.87M -2.75B
Logo ICAD
iCAD Inc is a United States‑based company. The Company develops artificial intelligence solutions designed to support healthcare providers in the detection and diagnosis of cancer. The company focuses on providing clinically proven AI technologies that assist medical professionals in identifying cancer earlier, improving diagnostic accuracy, and enhancing workflow efficiency. Its solutions include platforms for cancer detection, breast density assessment, and risk evaluation, enabling clinicians to analyze medical images and support patient care decisions. The company leverages advanced data, clinical evidence, and AI‑driven technologies to deliver tools that integrate into existing healthcare systems and assist in screening and diagnostic processes across global markets.
Employees
66
  1. Stock Market
  2. Stocks
  3. ICAD Stock